Originally published as JCO Early Release 10.1200/JCO.2006.09.6578 on August 6 2007

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, I. E. Articles by Dowsett, M. Search for Related Content PubMed PubMed Citation Articles by Smith, I. E. Articles by Dowsett, M. Social Bookmarking                            What's this?

A Phase II Placebo-Controlled Trial of Neoadjuvant Anastrozole Alone or With Gefitinib in Early Breast Cancer

Ian E. Smith, Geraldine Walsh, Anthony Skene, Antonio Llombart, José Ignacio Mayordomo, Simone Detre, Janine Salter, Emma Clark, Patrick Magill, Mitch Dowsett

From the Royal Marsden Hospital and Institute of Cancer Research; Royal Marsden Hospital, London; Royal Bournemouth Hospital, Bournemouth; AstraZeneca, Macclesfield, United Kingdom; Hospital Arnau I Vilanova, Lleida; and Hospital Lozano Blesa, Zaragoza, Spain.

Address reprint requests to Ian E. Smith, MD, Breast Unit, The Royal Marsden Hospital, Fulham Rd, London, SW3 6JJ United Kingdom; e-mail: ian.smith{at}rmh.nhs.uk

Purpose Increased epidermal growth factor receptor (EGFR) expression may promote breast cancer resistance to endocrine therapy. We have therefore investigated whether neoadjuvant gefitinib, an EGFR inhibitor, might overcome biologic and clinical resistance to neoadjuvant anastrozole in a phase II placebo-controlled trial.

Patients and Methods Postmenopausal women with stage I to IIIB hormone receptor–positive early breast cancer received anastrozole 1 mg daily for 16 weeks and were randomly assigned at a ratio of 2:5:5 to receive, in addition, gefitinib 250 mg/d orally for 16 weeks: placebo 1 tablet/d orally for 2 weeks and then gefitinib for 14 weeks or placebo for 16 weeks. The primary end point was biologic change in proliferation as measured by Ki67 at 2 and 16 weeks; the main secondary end point was overall objective response (OR).

Results Two hundred six women were randomly assigned. Mean changes in Ki67 with anastrozole and gefitinib versus anastrozole alone were –77.4% and –83.6%, respectively, between baseline and 16 weeks (geometric mean ratio = 1.37; 95% CI, 0.79 to 2.39; P = .26), –80.1% and –71.3% between baseline and 2 weeks (geometric mean ratio = 0.70; 95% CI, 0.39 to 1.25; P = .22) and –19.3% and –43% (geometric mean ratio = 1.42; 95% CI, 0.86 to 2.35; P = .16) between 2 and 16 weeks. ORs in the combination and anastrozole alone groups were 48% and 61% (estimated difference = –13.1%; 95% CI, –27.3% to 1.2%), respectively, with a nonsignificant trend against the combination (P = .08) and 48% versus 72% (estimated difference = –24.1%; 95% CI, –45.3% to –2.9%) in the progesterone-receptor–positive subgroup, which was significant (P = .03) and consistent with Ki67 changes. Common treatment-related adverse events included diarrhea, rash, alopecia, dry skin, and nausea. There was no evidence of a pharmacokinetic interaction.

Conclusion Addition of gefitinib to neoadjuvant anastrozole had no additional clinical or biologic effect, failing to support our original hypothesis.

published online ahead of print at www.jco.org on August 6, 2007.

Supported by a research grant from AstraZeneca.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. D. Green, P. A. Francis, V. Gebski, V. Harvey, C. Karapetis, A. Chan, R. Snyder, A. Fong, R. Basser, J. F. Forbes, et al. Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer Ann. Onc., November 1, 2009; 20(11): 1813 - 1817. [Abstract] [Full Text] [PDF]

				N. Normanno, A. Morabito, A. De Luca, M. C. Piccirillo, M. Gallo, M. R Maiello, and F. Perrone Target-based therapies in breast cancer: current status and future perspectives Endocr. Relat. Cancer, September 1, 2009; 16(3): 675 - 702. [Abstract] [Full Text] [PDF]

				S. Banerjee, S. Pancholi, R. A'Hern, Z. Ghazoui, I. E. Smith, M. Dowsett, and L.-A. Martin The Effects of Neoadjuvant Anastrozole and Tamoxifen on Circulating Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor 1 in Breast Cancer Clin. Cancer Res., May 1, 2008; 14(9): 2656 - 2663. [Abstract] [Full Text] [PDF]

				R. A. Lubet, E. Szabo, K. Christov, A. M. Bode, M. E. Ericson, V. E. Steele, M. M. Juliana, and C. J. Grubbs Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes Mol. Cancer Ther., April 1, 2008; 7(4): 972 - 979. [Abstract] [Full Text] [PDF]

				N. U. Lin and E. P. Winer Advances in Adjuvant Endocrine Therapy for Postmenopausal Women J. Clin. Oncol., February 10, 2008; 26(5): 798 - 805. [Abstract] [Full Text] [PDF]

				S. Massarweh, C. K. Osborne, C. J. Creighton, L. Qin, A. Tsimelzon, S. Huang, H. Weiss, M. Rimawi, and R. Schiff Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function Cancer Res., February 1, 2008; 68(3): 826 - 833. [Abstract] [Full Text] [PDF]

				M. Dowsett Factors Predicting Response and Resistance to Endocrine Therapy of Breast Cancer ASCO Educational Book, January 1, 2008; 2008(1): 14 - 17. [Abstract] [Full Text] [PDF]